Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCT400 vs Rituximab PK/PD in CD20-positive B-cell NHL
CTR20150086Phase 2Completed
- Sponsor
- Shenzhou Cell Engineering Co., Ltd.
- Start
- May 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ripertamab in mature B-cell lymphoma, sponsored by Shenzhou Cell Engineering Co., Ltd.. Started May 2015; status: completed.
02
Drugs
ripertamab
03
Conditions
mature B-cell lymphoma
Beyond the preview
Go deeper on CTR20150086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150086.